543 related articles for article (PubMed ID: 37197397)
1. Precision medicine and drug optimization in adult inflammatory bowel disease patients.
Vieujean S; Louis E
Therap Adv Gastroenterol; 2023; 16():17562848231173331. PubMed ID: 37197397
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
4. Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.
Sinopoulou V; Gordon M; Akobeng AK; Gasparetto M; Sammaan M; Vasiliou J; Dovey TM
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013531. PubMed ID: 34844288
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine in inflammatory bowel disease.
Zeng Z; Jiang M; Li X; Yuan J; Zhang H
Precis Clin Med; 2023 Dec; 6(4):pbad033. PubMed ID: 38638127
[TBL] [Abstract][Full Text] [Related]
7. Integration and implementation of precision medicine in the multifaceted inflammatory bowel disease.
Jagirdhar GSK; Perez JA; Perez AB; Surani S
World J Gastroenterol; 2023 Sep; 29(36):5211-5225. PubMed ID: 37901450
[TBL] [Abstract][Full Text] [Related]
8. Visceral adiposity and inflammatory bowel disease.
Rowan CR; McManus J; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.
Saniabadi AR; Tanaka T; Ohmori T; Sawada K; Yamamoto T; Hanai H
World J Gastroenterol; 2014 Aug; 20(29):9699-715. PubMed ID: 25110409
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive review and update on Crohn's disease.
Gajendran M; Loganathan P; Catinella AP; Hashash JG
Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
[TBL] [Abstract][Full Text] [Related]
12. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory Bowel Disease Treatments and Predictive Biomarkers of Therapeutic Response.
Elhag DA; Kumar M; Saadaoui M; Akobeng AK; Al-Mudahka F; Elawad M; Al Khodor S
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805965
[TBL] [Abstract][Full Text] [Related]
14. Precision Medicine in Pediatric Inflammatory Bowel Disease.
Spencer EA; Dubinsky MC
Pediatr Clin North Am; 2021 Dec; 68(6):1171-1190. PubMed ID: 34736583
[TBL] [Abstract][Full Text] [Related]
15. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.
Bernstein CN; Benchimol EI; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Kaplan GG
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S73-S80. PubMed ID: 31294387
[TBL] [Abstract][Full Text] [Related]
17. Precision Medicine in Inflammatory Bowel Disease.
Annese V; Annese M
Diagnostics (Basel); 2023 Aug; 13(17):. PubMed ID: 37685335
[TBL] [Abstract][Full Text] [Related]
18. Inflammatory bowel disease. Part II: Clinical and therapeutic aspects.
Kirsner JB
Dis Mon; 1991 Nov; 37(11):669-746. PubMed ID: 1935537
[TBL] [Abstract][Full Text] [Related]
19. Integrating omics for a better understanding of Inflammatory Bowel Disease: a step towards personalized medicine.
Kumar M; Garand M; Al Khodor S
J Transl Med; 2019 Dec; 17(1):419. PubMed ID: 31836022
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
